In today's volatile, uncertain, complex and ambiguous environment, organizational resilience is a strategic capability to stay afloat "stormy waters" when faced with business disruptions that have grave impacts on the organization's business operations, supply chain, and reputation. A true resilient organization needs to be constantly scanning for potential threats, identify the probable risks, plan and be prepared to deal with the consequences and impacts when the risks materialize. However, many organizations approached this capability in varied methodologies with some focusing on business continuity while others are emphasizing on crisis management. This paper uncovers the converging domains-interplays between the concepts and the building blocks of enterprise risk and resource management, emergency and crisis management, business continuity and disaster recovery management to act as the bedrock to achieve business resilience through the Incident Management Body of Knowledge as the amalgamated framework for total resilient capability; using the Adaptive Incident Management Methodology, to enable organizations to build an "Adaptive System: Integrated Approach, Dynamic Response" to the management of all-risks and all-hazards incidents. is closely linked to the organization's ability to manage the elements that contribute to business disruptions that impact future business in the supply chain, operations, products, services, customer relations, and even public confidence. A truly resilient organization need to have the foresight to recognize potential risks with ongoing size-up of operating environment to prevent unwanted disruption or possible creeping crisis from emerging, and in the event of an unwanted incident, the ability to detect, respond, intervene, adjust, and recover from the

An allometric target organ dose model (TOD-W b ) with variable scaling exponent, b = br + bo(bm) -bi, is proposed for the extrapolation of animal toxicity to human. The exponent b comprises four constituent parameters representing the intake mode to entry organ (bi), route of transportation to target organ (br), mass of target organ (bo), and rate of metabolism at target organ (bm). This expression enables the a priori determination of b from known values of bi, br, bo, and bm. From nipradilol that target the respiratory system, the br values determined for intragastric (ig), intraperitoneal (ip), intravenous (iv), and subcutaneous (sc) injections were 0.15, 0.26, 0.03, and 0.61, respectively; from HF mouth breathing data, the br value is 0.07 for pulmonary absorption through inhalation (ih); and from actinomycin D data that target bone marrow through the ip-route, the bo value is 0.53. The model is tested with the parameter values obtained from literature; validating the a priori values determined in this paper with the empirical values measured. For ip-administration of OMPA and parathion, the a priori [3/4(bo) -1] value and empirical value are -0.475 and -0.48; for nine alkylating agents, the values are -0.60 and -0.61; for ig-administration of NaCN, the [br + 3/4(bo) -1] and empirical values are -0.1 and -0.092, respectively. The analysis of toxic gas inhalation data in student projects are also summarized herein. Consequently, values of these parameters can also be estimated by fitting known toxicity data to the TOD-W b model.